LN

LENSAR IncNASDAQ LNSR Stock Report

Last reporting period 30 Jun, 2024

Updated 22 Nov, 2024

Last price

Market cap $B

0.051

Micro

Exchange

XNAS - Nasdaq

LNSR Stock Analysis

LN

Uncovered

LENSAR Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

14/100

Low score

Market cap $B

0.051

Dividend yield

Shares outstanding

11.103 B

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 110 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company has developed the LENSAR Laser System to provide an alternative laser cataract treatment tool that allows the surgeon to better address astigmatism and improve visual outcomes. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The firm is also developing an integrated cataract treatment system, ALLY Adaptive Cataract Treatment System (ALLY). The ALLY system is designed to combine its existing femtosecond laser technology and a phacoemulsification system into a single unit that allows surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.

View Section: Eyestock Rating